Development of a sublingual mucosal immunization technology platform for needle-free vaccination
Project goals
Development of sublingual delivery module Development of vaccine formulation In vitro testing of vaccine formulation In vivo testing of vaccine formulation Laboratory analysis of immunity Project IP and management
Keywords
Public support
Provider
Ministry of Education, Youth and Sports
Programme
Eurostars
Call for proposals
SMSM20197D001
Main participants
InStar Technologies a.s.
Contest type
VS - Public tender
Contract ID
MŠMT-4048/2019-4
Alternative language
Project name in Czech
Development of a sublingual mucosal immunization technology platform for needle-free vaccination
Annotation in Czech
Development of sublingual delivery module Development of vaccine formulation In vitro testing of vaccine formulation In vivo testing of vaccine formulation Laboratory analysis of immunity Project IP and management
Scientific branches
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
The main goal of the MucoVAC project was the technology development for oromucosal vaccine delivery (needle-free) which should be tested with the model antigen (influenza). The mentioned goal of the project was achieved, the technology was developer and validated. The outputs containing 3 different types of antigen were achieved. Tests on mouse and pig models confirmed that the designed dosing module was able to carry the active substance without damaging the structure, release it, sufficient protection from the surrounding environment and thus allow "safe" transport to the destination. An immune response was elicited in both animal models. SL immunization of pigs activated T and B cells in local tissues that are statistically significantly increased compared to those in pigs receiving the vaccine by the MI route. Here again, SL application appeared to be more effective compared to the IM application, as shown by a significantly increased number of antigen-specific B cells (P < 0.05).
Solution timeline
Realization period - beginning
Jun 1, 2019
Realization period - end
Apr 30, 2022
Project status
U - Finished project
Latest support payment
May 6, 2022
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP23-MSM-7D-U
Data delivery date
Jun 30, 2023
Finance
Total approved costs
20,110 thou. CZK
Public financial support
8,871 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
8,045 thou. CZK
Recognised costs
20 110 CZK thou.
Public support
8 871 CZK thou.
0%
Provider
Ministry of Education, Youth and Sports
OECD FORD
Health-related biotechnology
Solution period
01. 06. 2019 - 30. 04. 2022